London-based Boltz, which is developing AI models to speed up drug discovery, raised a $110M Series A led by Bessemer, after raising a $28M seed in 2025
First reported by Tech.eu ·
AI-driven drug discovery platforms can now command nine-figure funding rounds, signaling a new economic reality for biotech R&D.
London-based Boltz, an AI startup focused on accelerating drug discovery, has secured $110 million in a Series A funding round. The round was led by Bessemer Venture Partners and included participation from existing investors such as Andreessen Horowitz, Amplify Partners, Zetta Venture Partners, and Obvious Ventures. Boltz, which spun out of MIT, employs 40 AI researchers and emerged from stealth less than a year ago. The company develops AI models specifically designed to expedite the process of discovering new drugs. This significant funding follows a prior $28 million seed round raised in 2025, indicating strong investor confidence in Boltz's technology and market potential.
The substantial Series A valuation for Boltz underscores a significant trend: the increasing integration of advanced AI, particularly large language models and generative AI, into the core of pharmaceutical research and development. This move from theoretical applications to substantial capital investment indicates that the industry is rapidly shifting towards AI-native approaches for target identification, molecule design, and clinical trial optimization. The speed at which Boltz has progressed from seed to a large Series A in under a year suggests a maturing ecosystem for AI in life sciences, with investors recognizing the potential for AI to dramatically reduce the time and cost associated with bringing new therapeutics to market.
This influx of capital into AI drug discovery startups like Boltz is poised to reshape the competitive landscape for both established pharmaceutical giants and smaller biotech firms. Companies that effectively leverage AI models stand to gain a substantial advantage in identifying novel drug candidates and navigating complex research pipelines, potentially leading to faster drug approvals and more personalized treatments. The success of this funding round may also spur further investment in similar ventures and encourage traditional pharma companies to accelerate their adoption of AI technologies, either through internal development or strategic partnerships.
AI-written summary. May contain errors.